ImmunoCellular Therapeutics Ltd.
IMUC.WS
IMUC.WS was delisted on the 16th of October, 2018.
5 hedge funds and large institutions have $110K invested in ImmunoCellular Therapeutics Ltd. in 2017 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and closing their positions.
25% more funds holding
Funds holding: 4 → 5 (+1)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
78% less capital invested
Capital invested by funds: $511K → $110K (-$401K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VKH
Virtu KCG Holdings
New York
|
+$3.76K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$1.59K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$639 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AFM
1
Anson Funds Management
Dallas,
Texas
| $100K | – | – | – |
|
|
SM
2
Sabby Management
Miami Beach,
Florida
| $8K | -$639 | -3,664 | -0.9% |
|
3
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $2K | – | – | – |
|
|
4
UBS Group
Zurich,
Switzerland
| – | +$1.59K | +9,140 | +691% |
|
|
VKH
5
Virtu KCG Holdings
New York
| – | +$3.76K | +21,526 | New |
|
IMUC.WS Hedge Fund Activity: Q2 2017 in Review
5 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in ImmunoCellular Therapeutics Ltd. (IMUC.WS) for Q2 2017, worth a combined $110K — down 78% from $511K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new IMUC.WS positions and 0 closed out — a net gain of 1 holder — while 1 added to existing stakes and 1 trimmed.
The largest buyer was Virtu KCG Holdings, opening a new position worth an estimated $3.76K. The largest seller was Sabby Management, cutting an estimated $639.
- 5 institutional investors held ImmunoCellular Therapeutics Ltd. (IMUC.WS) as of Q2 2017, up from 4 in Q1 2017.
- Funds reported $110K of ImmunoCellular Therapeutics Ltd. stock for Q2 2017, down 78% quarter-over-quarter.
- 1 fund opened new ImmunoCellular Therapeutics Ltd. positions in Q2 2017 and 0 closed out, a net change of +1 holder.
- The largest ImmunoCellular Therapeutics Ltd. buyer in Q2 2017 was Virtu KCG Holdings, an estimated $3.76K added.
- The largest ImmunoCellular Therapeutics Ltd. seller in Q2 2017 was Sabby Management, an estimated $639 sold.
Based on aggregated 13F filings for Q2 2017.